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ABSTRACT
Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of 
AML patients and is highly heterogeneous. Whereas adverse and favourable risk 
patients have well-established treatment protocols, IR-AML patients have not. It 
is, therefore, crucial to find novel factors that stratify this subgroup to implement 
risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family 
regulates cell proliferation, survival, migration and adhesion. Despite its association 
with metastatic dissemination and prognosis of different solid tumors, the role of these 
proteins in hematological malignancies has been scarcely evaluated. Nevertheless, 
previous work has established an important role for the CAS family members NEDD9 
or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this 
basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with 
survival in IR-AML patients and become new prognostic markers. To that purpose, 
we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients 
validating the results in an independent cohort (n = 206). We have identified NEDD9, 
but not BCAR1, as a new a marker for longer overall and disease-free survival, and 
for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an 
independent prognostic factor for favourable prognosis in IR-AML patients.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous 
group of diseases characterized by the infiltration of bone 
marrow, blood, and other tissues by proliferative, clonal 
and abnormally differentiated immature cells of the 
hematopoietic system [1–3]. 
According to cytogenetic and molecular features, 
AML patients are classified into favorable, intermediate, or 
adverse risk groups and their therapy after remission are risk-
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adapted [2]. Although many favorable and adverse group 
patients are well characterized by specific chromosomal 
alterations, the intermediate-risk cytogenetics group (IR-
AML) is heterogeneous and includes patients with a widely 
diverse outcome. In contrast to established treatment 
protocols for patients in the favorable and adverse risk 
groups, the clinical decision guideline for the IR-AML group 
remains unclear [4]. This uncertainty regarding therapy 
impairs survival of many IR-AML patients. Therefore, there 
is a need to find new prognostic factors to stratify this group 
of patients allowing clinicians to choose better treatments 
and improve their outcome. For that reason, several genetic 
alterations have been evaluated over the last years in an 
attempt to improve patient stratification of the IR-AML 
group. At present, only the molecular markers NPM1, 
CEBPA and FLT3 have been incorporated into clinical 
practice [2, 5, 6]. For instance, a combination of mutated 
NPM1 and non-mutated FLT3/Internal tandem duplication 
(FLT3/ITD) associates with favorable outcome in IR-AML 
patients [7–10]. Similarly, biallelic CEBPA mutations predict 
a relatively favorable outcome in patients without FLT3/ITD 
[11]. Recently, mutations of RUNX1, ASXL1 and TP53 
have been associated with adverse outcome and are also 
included in the standard diagnosis [4]. Additional molecular 
factors, such as IDH1, IDH2, TET2, DNMT3A, MLL-PTD 
or NRAS, have demonstrated capacity to stratify a subset of 
IR-AML patients, allocating to them into the  good or poor 
prognosis groups [12, 13]; nevertheless, they have not been 
introduced in clinical practice yet; therefore the need still 
remains to identify new prognostic indicators with higher 
stratification capacity.
The Crk-Associated Substrate (CAS) is a family of 
focal adhesion related proteins that play crucial roles in the 
regulation of cell growth, adhesion, migration and apoptosis 
[14]. They are involved in signal transduction downstream of 
integrin engagement and receptor tyrosine kinases (RTKs), 
which signal through the FAK, SRC and CAS family proteins. 
In this context, upregulation of scaffolding proteins such as 
NEDD9 or BCAR1, and also of the FAK and SRC protein 
kinases, has shown pro-metastatic capacity in different solid 
tumors and associates with poor outcome [14, 15]. The role 
of focal adhesion proteins in hematologic malignancies has 
been less studied. In this regard, FAK and SRC are prognostic 
factors that associate with poor outcome in AML [16, 17]. 
In the present study, we investigated whether NEDD9 and 
BCAR1 could have prognostic significance and correlate 
with survival in IR-AML patients. We have found, in two 
independent patient cohorts, the expression of NEDD9, but 
not BCAR1, to be an independent prognostic factor in IR-
AML patients, that associates with better outcome.
RESULTS
Patient characteristics
The main characteristics of the patients from the two 
cohorts are shown in Table 1. In summary, the Cohort 1 
had 73 patients, while the Cohort 2 had 206 patients. The 
median ages were 52 and 53 years with a 47% and a 43% 
of patients younger than 50 years, respectively. Most of 
the characteristics, including age, gender, NPM1 and 
FLT3/NPM1 combined mutations did not show significant 
differences between the two cohorts. However, in Cohort 1, 
the median of white blood cells (WBC) count, the 
percentage of patients with the WBC count over 20 × 109/L, 
FLT3/ITD+ and CEBPA- were significantly higher than in 
Cohort 2. The percentage of patients in some subgroups of 
the French-American-British (FAB) classification was also 
significantly different between cohorts. 
Clinical outcomes such as overall survival (OS) 
and disease-free survival (DFS) between the two cohorts 
did not present statistically significant differences (OS, 
p = 0.610; DFS, p = 0.904) (Data not shown).
The alive patients had a median follow-up of 56 and 
58 months in the Cohort 1 and 2, respectively, and the OS 
at 5 years for the patients of the two groups were 47.0 ± 6.1 
% and 48.8 ± 3.7 %, respectively (Supplementary Table 1). 
After a median follow-up for patients alive or in 
complete remission (CR) of 54 months in Cohort 1 and 
46 months in Cohort 2, 29% (17/59) and 35% (64/185) 
of patients in Cohorts 1 and 2 respectively, relapsed 
(Supplementary Table 1). At 5 years, DFS for patients 
of two groups were 51.4 ± 6.6 and 44.8 ± 4.1 % and 
cumulative incidence of relapse (CIR) were 29.6 ± 6.1 and 
37.8 ± 3.9 %, respectively. None of the variables analyzed 
(age, FLT3/ITD duplication and FLT3/NPM1 combined 
mutations) in Cohort 1 had an impact on DFS or CIR. In 
contrast, in Cohort 2, patients older than 50 years, with 
FLT3/ITD mutation or with the unfavorable FLT3/NPM1 
combination (FLT3+/NPM1−, FLT3−/NPM1− and FLT3+/
NPM1+) showed the worst survival after a CR and a 
higher incidence of relapse than younger patients, patients 
without FLT3/ITD or with a favorable FTL3/NPM1 
combination (FLT3−/NPM1+) (Supplementary Table 1). 
Furthermore, 52% (38/73) and 49% (101/206) 
of patients in Cohort 1 and 2, respectively, died 
(Supplementary Table 1).
NEDD9 is an independent prognostic factor for 
OS and DFS in IR-AML patients
Clinical variables as age, sex, WBC, FLT3/ITD 
duplication, NPM1 mutation and FLT3/NPM1 combined 
mutations, as well as BCAR1 and NEDD9 expression 
were assessed in the univariate analysis. The variables 
with a p-value higher than 0.25 were not included in the 
multivariate analysis.
In order to establish the cutoff for BCAR1 and 
NEDD9 expression, we performed ROC (Receiver 
Operating Characteristic) curves. However, we could not 
find any point with enough specificity and sensitivity. 
Thus, we decided to perform exploratory univariate 
analyses using the mean, the median or the quartiles as 
thresholds. In BCAR1 analyses, no statistically significant 
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difference was found with any cutoff. On the contrary, 
when we used the mean as threshold we found NEDD9 
as a good prognostic factor of OS in Cohort 1 (p = 0.003) 
and DFS in the two cohorts (Cohort 1 p = 0.019 and 
Cohort 2 p = 0.046). Using the median as threshold, 
NEDD9 expression was significant in two clinical 
outcome endpoints (OS p = 0.009 and DFS p = 0.003) in 
the Cohort 1, in contrast, in the Cohort 2 it was not in any 
of them. Finally, when we established the third quartile as 
the cutoff we found the best results in both cohorts, so we 
decided to perform all the analysis using the third quartile 
to define overexpression of NEDD9. 
In the univariate analysis of Cohort 1 (Tables 2 and 3), 
Cox regression and Fine and Gray’s tests showed that 
Table 1: Patient’s characteristics and comparison between the cohorts of our study
Parameter
Cohort 1 Cohort 2
P
(n = 73) (n = 206)
    
Age, median (range) 52 (17–65) 53 (17–65) 0.187†
 < 50 years (%) 34 (47) 88 (43) 0.585
 > 50 years (%) 39 (53) 118 (57)  
Sex,    
 Male (%) 39 (53) 109 (53) 1.000
 Female (%) 34 (47) 97 (47)  
WBC, median (range) 60 (2–325) 16 (0–324) < 0.001‡
 < 20 × 109/L (%) 25 (34) 107 (53) 0.009
 > 20 × 109/L (%) 48 (66) 97(47)  
FAB Classification (%)   0.045*
 M0 8 (11) 16 (8)  
 M1 23 (32) 47 (23)  
 M2 6 (8) 41 (20)  
 M4 12 (16) 37 (18)  
 M4E 1 (1) 1 (1)  
 M5 21 (29) 46 (22)  
 M6 1 (1) 6 (3)  
 M7 1 (1) 0 (0)  
 Unknown 0 (0) 12 (6)  
Molecular alterations (%)    
 FLT3/ITD− 39 (53) 149 (72) 0.023
 FLT3/ITD+ 29 (40) 56 (27)  
 Unknown 5 (7) 1(1)  
 NPM1− 31 (43) 108 (52) 0.570
 NPM1+ 33 (45) 97 (47)  
 Unknown 9 (12) 1 (1)  
 FLT3− + NPM1+ (Favorable) 16(22) 60(29) 0.633
 Others (Unfavorable) 47(64) 145(70)  
 Unknown 10(14) 1(1)  
 CEBPA− 57(78) 78(38) < 0.001*
 CEBPA+ 1(1) 11(5)  
 Unknown 15(21) 117(57)  
Results are presented as the number of patients for each characteristic. The percentage of the patients is indicated in brackets 
for each condition. For categorical variables, the Fischer exact test or χ2 test (*) were used to analyze the statistical significance; 
while for continuous variables showing normal or abnormal distribution, the Student’s t-test (†) or the Mann-Whitney U (‡) 
test were used, respectively. P < 0.05 indicates statistical significance (Bold values). WBC; White blood cells. FAB; French-
American-British.
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age over 50 years and NEDD9 overexpression (over the 
third quartile) were associated with lower and higher OS, 
respectively (p = 0.031, Hazard Ratio (HR) = 2.071; p = 
0.026, HR = 0.343, resp.). Regarding DFS, only NEDD9 
expression showed a trend towards significance (p = 0.067) 
while any variable was significant in the CIR univariate 
analyses. In Cohort 2 analyses, NEDD9 expression 
(overexpression), and FLT3/NPM1 combination 
(unfavorable combinations: FLT3+/NPM1−, FLT3−/NPM1− 
and FLT3+/NPM1+) had significant differences in OS 
(p = 0.029, HR = 0.566; p = 0.002, HR = 2.243, resp.), 
DFS (p = 0.006, HR=0.468; p = 0.002, HR = 2.229, resp.) 
and CIR (p = 0.040, HR=0.519; p = 0.016, HR = 2.030, 
resp.) studies. Moreover, age (> 50 years) in OS and 
DFS (p = 0.008, HR = 1.761; p = 0.038, HR = 1.555, 
resp.), NPM1 (NPM1+) in OS (p = 0.045, HR = 0.658) 
and FLT3/ITD duplication (FLT3/ITD+) in DFS and CIR 
(p = 0.025, HR = 1.636; p = 0.016, HR = 1.720, resp.) 
were also statistically significant. BCAR1 expression had 
no differences in any univariate analyses of any cohort.
In multivariate analyses for NEDD9 (Tables 2 and 3), 
all of these variables kept their statistical significance except 
for NPM1 mutation in OS, FLT3/ITD duplication in DFS 
and CIR, and FLT3/NPM1 combined mutations in CIR of 
Cohort 2. Moreover, in Cohort 1 study, although the NEDD9 
expression had a p-value of 0.067 in the univariate analysis 
in DFS (HR = 0.372), it showed significant differences in 
the multivariate analysis (p = 0.030, HR = 0.304). 
In all cases with statistical significance, age over 50 
years, FLT3/NPM1 unfavorable combinations and FLT3/
ITD duplication had a HR above 1, whereas the HR of 
NEDD9 overexpression and NPM1 mutation was lower 
than 1.
Survival curves
Kaplan-Meier analysis showed that patients with 
overexpression of NEDD9 (over the third quartile) had 
better prognosis than patients with lower expression of 
NEDD9 (Figures 1 and 2). Significantly, the Cohort 1 
patients with overexpression of NEDD9 had an increase 
in OS (69.3 ± 11.6 vs 34.2 ± 7.9%, p = 0.020) (Figure 1), 
which was validated by the Cohort 2 analysis (62.4 ± 7.1 
vs 42.1 ± 4.6%, p = 0.027). In addition, in the Cohort 1 
patients with NEDD9 overexpression showed a clear trend 
towards significance in predicting better DFS (70.1 ± 12.6 
vs 39.0 ± 8.8%, p = 0.056) (Figure 1). Indeed, this 
difference reached significance in the Cohort 2 due to 
its higher number of patients (59.6 ± 8.3 vs 35.6 ± 5.0%, 
p = 0.005). In a similar way, although the differences 
between patients that overexpressed and underexpressed 
NEDD9 in the Cohort 1 were not statistically significant in 
CIR analyses (22.1 ± 11.8 vs 32.0 ± 7.2%, p = 0.417), the 
same study in Cohort 2 presented significant differences 
(CIR: 29.2 ± 8.0 vs 45.0 ± 5.2%, p = 0.036) (Figure 2). No 
differences were found in the Kaplan-Meier analyses of 
BCAR1 expression (Supplementary Figure 1).
Association of NEDD9 expression with clinical 
and molecular characteristics of AML patients
NEDD9 association with several variables such as 
age, sex, WBC, FAB classification, FLT3/ITD duplication, 
NPM1 mutation, FLT3/NPM1 combined mutations, 
disease status (relapsed or no relapsed) and patient status 
at the end of follow up (alive or death) was evaluated 
in each cohort. Most of the variables analyzed had no 
association with the NEDD9 expression (Table 4). Only 
FAB classification and the patient status at the end of the 
study (alive or death) showed significant association with 
NEDD9 expression.
DISCUSSION
A remarkable proportion of patients included in 
the intermediate-risk cytogenetics group show diverse 
outcome. In the last decades, an effort has been made 
to identify novel molecular markers that could improve 
patient stratification in order to adapt their therapy to 
their prognosis. Up to now, only the analyses of NPM1, 
CEBPA and FLT3/ITD mutations have effectively been 
incorporated into routine prognostic stratification [6]. More 
recently, the mutations of RUNX1, TP53 and ASXL1 have 
been also associated with unfavorable outcome [4].
In the present study, we have identified for the 
first time, in two independent cohorts, that NEDD9 
overexpression is a favorable prognostic factor in 
intermediate-risk AML patients. This was, however, an 
unexpected finding since NEDD9 confers aggressiveness 
in most cancer types studied so far [14, 15]. A review of 
the NEDD9 published literature provided a rationale for 
our findings by identifying a distinct function for NEDD9 
in normal and neoplastic myeloid cells as compared to 
normal lymphocytes or epithelial cells and their derived 
malignancies.
NEDD9 is a member of the CAS family of adhesion 
docking proteins. In adherent cells, NEDD9 regulates 
several signaling cascades involved in multiple activities 
including migration, adhesion, cell death or proliferation 
[18–20]. Because of the involvement of NEDD9 in key 
cellular functions, it is not surprising that a link has been 
established between its aberrant expression or activation 
and the aggressiveness or metastatic capacity of cancer 
cells [15]. Thus, overexpression of NEDD9 correlated 
with cell migration, invasion, metastasis development and 
drug resistance in several types of solid tumors such as 
glioblastoma, melanoma or breast cancer [19, 21].
However, NEDD9 shows opposite effects regarding 
migratory capacity on myeloid cells as compared to 
epithelial or lymphoid cells. Thus, NEDD9 blocks 
normal myeloid cell migration since NEDD9 deficient 
neutrophils [22], granulocytes or macrophages display 
increased migratory activity [23]. In sharp contrast, 
NEDD9 promotes migration in cultured normal human 
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embryonic kidney cells [24] or fibroblasts [20], an effect 
occurring also in lymphocytes since NEDD9 deficient 
B cells show decreased migration as compared their 
wild type counterparts [22, 25]. The direction of the 
differences in normal cell migration between cells of 
the myeloid and lymphoid lineages observed in vitro 
is maintained in in vivo models. Thus, as compared to 
NEDD9+/+ mice, NEDD9 −/− mice show an increased 
number of macrophages, and a simultaneous reduction 
of B lymphocytes in peripheral blood [26] and secondary 
lymphoid organs, yielding an almost complete loss of 
Marginal Zone B (MZB) cells in the spleen [25]. 
The distinct NEDD9 functions observed in normal 
cells persist after neoplastic transformation, since NEDD9 
Table 2: Univariate and multivariate analyses of NEDD9, BCAR1 and clinical variables in OS and 
DFS
Cohort 1 (n = 73) Cohort 2 (n = 204)
OS Univariate Multivariate Univariate Multivariate
Variable Item HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age  < 50 years 1 1
 > 50 years 2.071 (1.067–4.018) 0.031 2.542 (1.290–5.011) 0.007 1.761 (1.159–2.676) 0.008 2.011 (1.311–3.085) 0.001
Sex  Male 1 1
 Female 1.701 (0.898–3.221) 0.103 1.636 (0.859–3.116) 0.134 0.808 (0.543–1.202) 0.292 – – –
WBC  < 20 × 109/L 1 1
 > 20 × 109/L 0.709 (0.370–1.361) 0.301 – – – 1.019 (0.685–1.515) 0.926 – – –
FLT3  FLT3/ITD– 1 1
 FLT3/ITD+ 1.071 (0.555–2.067) 0.839 – – – 1.315 (0.851–2.031) 0.217 1.080 (0.541–2.153) 0.828
NPM1  NPM1– 1 1
 NPM1+ 1.252 (0.628–2.495) 0.523 – – – 0.658 (0.438–0.991) 0.045 1.112 (0.513–2.408) 0.788
FLT3/NPM1 Favorable 1 1
Unfavorable 1.222 (0.527–2.832) 0.640 – – – 2.243 (1.344–3.745) 0.002 2.686 (1.047–6.889) 0.040
NEDD9 Underexpression 1 1
Overexpression 0.343 (0.134–0.883) 0.026 0.243 (0.085–0.698) 0.009 0.566 (0.339–0.944) 0.029 0.582 (0.341–0.995) 0.048
BCAR1 Underexpression 1 1
Overexpression 0.765 (0.330–1.773) 0.532 – – – 0.925 (0.569–1.506) 0.755 – – –
Cohort 1 (n = 59) Cohort 2 (n = 185)
DFS Univariate Multivariate Univariate Multivariate
Variable Item HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age  < 50 years 1 1
 > 50 years 1.642 (0.782–3.448) 0.191 2.053 (0.962–4.381) 0.063 1.555 (1.024–2.360) 0.038 1.845 (1.203–2.829) 0.005
Sex  Male 1 1
 Female 1.276 (0.615–2.646) 0.513 – – – 0.853 (0.570–1.279) 0.442 – – –
WBC  < 20 × 109/L 1 1
  < 20 × 109/L 0.695 (0.332–1.455) 0.335 – – – 1.041 (0.694–1.561) 0.846 – – –
FLT3  FLT3/ITD– 1 1
 FLT3/ITD+ 0.914 (0.424–1.971) 0.818 – – – 1.636 (1.063–2.519) 0.025 1.606 (0.998–2.584) 0.051
NPM1  NPM1– 1 1
 NPM1+ 1.369 (0.596–3.143) 0.459 – – – 0.793 (0.528–1.193) 0.266 – – –
FLT3/NPM1 Favorable 1 1
Unfavorable 1.247 (0.490–3.176) 0.643 – – – 2.229 (1.345–3.693) 0.002 2.079 (1.203–3.595) 0.009
NEDD9 Underexpression 1 1
Overexpression 0.372 (0.129–1.072) 0.067 0.304 (0.103–0.893) 0.030 0.468 (0.273–0.803) 0.006 0.426 (0.241–0.753) 0.003
BCAR1 Underexpression 1 1
Overexpression 0.782 (0.290–2.111) 0.628 – – – 0.947 (0.573–1.562) 0.830 – – –
COX test was used to analyze the statistical significance in OS and DFS. P value < 0.05 was considered statistically significant (Bold values). “-“ indicates that variables were not included in the multivariate 
analyses (P value > 0.250 in the univariate analysis). HR; Hazard ratio. CI; Confidence interval. OS; Overall survival. DFS, Disease-free survival. WBC; White blood cells.
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Table 3: Univariate and multivariate analyses of NEDD9, BCAR1 and clinical variables in CIR
Cohort 1 (n = 59) Cohort 2 (n = 185)
CIR Univariate Multivariate Univariate Multivariate
Variable Item HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age  < 50 years 1 1
 > 50 years 1.160 (0.453–2.970) 0.760 – – – 1.080 (0.656–1.770) 0.770 – – –
Sex  Male 1 1
 Female 0.842 (0.326–2.180) 0.720 – – – 1.030 (0.634–1.680) 0.900 – – –
WBC  < 20 × 109/l 1 1
 >20 × 109/l 2.110 (0.710–6.250) 0.180 2.080 (0.623–6.940) 0.230 1.090 (0.672–1.780) 0.720 – – –
FLT3  FLT3/ITD− 1 1
 FLT3/ITD+ 1.300 (0.714–2.370) 0.390 – – – 1.720 (1.100–2.680) 0.016 1.660 (0.911–3.024) 0.098
NPM1  NPM1− 1 1
 NPM1+ 0.875 (0.456–1.680) 0.690 – – – 0.814 (0.501–1.320) 0.410 – – –
FLT3/NPM1 Favorable 1 1
Unfavorable 6.360 (0.903–44.700) 0.063 6.050 (0.870–42.050) 0.069 2.030 (1.140–3.620) 0.016 1.615 (0.855–3.052) 0.140
NEDD9 Underexpression 1 1
Overexpression 0.606 (0.185–1.990) 0.410 – – – 0.519 (0.278–0.969) 0.040 0.441 (0.220–0.884) 0.021
BCAR1 Underexpression 1 1
Overexpression 0.578 (0.134–2.490) 0.460 – – – 0.767 (0.409–1.440) 0.410 – – –
Gray and Fine and Gray tests for CIR were used to analyze the statistical significance. P value < 0.05 was considered statistically significant (Bold values). “–“ indicates that variables were not included in the 
multivariate analyses (P value > 0.250 in the univariate analysis). HR; Hazard ratio. CI; Confidence interval. CIR; Cumulative incidence of relapse. WBC; White blood cells.
Figure 1: Survival according to NEDD9 expression in cohorts. Kaplan–Meier curves represent OS of cohort 1 (A) and cohort 2 
(B), and DFS of cohort 1 (C) and cohort 2 (D) depending on the NEDD9 expression. Black line and gray line indicate NEDD9 overexpressed 
and underexpressed, respectively. Log-rank test was used to analyze the statistical significance. P < 0.05 was considered statistically 
significant (Bold values). OS; Overall survival. DFS; Disease-free survival.
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overexpression blocks migration and dissemination of 
neoplastic cells of the myeloid lineage, while stimulating 
them in solid tumors or lymphoid neoplasias. Thus, 
NEDD9 inactivation associates with higher in vivo 
aggressiveness in chronic myeloid leukemia (CML), since 
NEDD9 deficient p210Bcr/Abl transgenic mice show an 
increased number of granulocytes in peripheral blood, a 
hyperplasia of myeloid and megakaryocytic cells in the 
bone marrow, and a diffuse myeloid infiltration in the 
spleen, lung and liver, leading to earlier progression and 
shorter mouse survival, which support NEDD9 capacity 
to block CML progression [23]. In contrast, NEDD9 
mediates dissemination in BCR-ABL-dependent acute 
lymphoblastic leukemia (ALL) showing  splenomegaly 
by accumulation of and pre-B cell lymphoblasts [21, 27]. 
Similarly, NEDD9 deficient p210Bcr/Abl mice show 
a significant decrease in lymphoid cell infiltration in 
bone marrow and spleen concomitantly with an increase 
in granulocytes [23]. In the same venue, in adult T-cell 
leukemia (ATL), the NEDD9 overexpression is induced 
by the Tax oncoprotein of the HTLV1 virus and enhances 
lymphocyte motility [28]. Finally, NEDD9 overexpression 
increases motility and/or induces epithelial-to-
mesenchymal transition (EMT) in melanoma, glioblastoma 
and  breast or colorectal carcinoma cells in vitro [29–32]. 
In addition, NEDD9 overexpression increases metastases 
and aggressiveness in in vivo models of these solid tumors 
[15, 19, 21, 33].
Based on the reports described above, the favorable 
prognosis we have observed for NEDD9 overexpression 
in IR-AML patients is consistent with the notion that 
overexpression of NEDD9 in AML cells may block their 
migratory and dissemination capacities, in contrast to the 
stimulation of in vitro migration or in vivo dissemination 
reported for cells on lymphoid or solid malignancies. 
There are some limitations in our study. One of 
them is the lack of the CEBPA mutation analysis in the 
clinical data that lead to their exclusion in the univariate 
and multivariate analyses. However, CEBPA mutations are 
rather infrequent and because of that, they are unlikely 
to have an impact on the observed associations, despite 
an unequal distribution among high and low NEDD9 
expression groups. Another limitation is that the prognostic 
value of NEDD9 cannot be extrapolated to patients older 
than 65 because they have not been included in this 
study. In addition, since minimal residual disease (MRD) 
status has been pointed out in recent studies as a strong 
prognostic factor for relapse and DFS in AML, it would 
be interesting to analyze the correlation between NEDD9 
expression and MRD status in the future. Unfortunately, 
the lack of MRD data for most of the studied patient cohort 
precluded this analysis. Nevertheless, our study is robust 
since NEDD9 has been validated as a prognostic factor in 
two independent cohorts and has also been confirmed in 
the multivariate analyses.
In summary, our study identifies NEDD9 
overexpression as a good prognostic factor in IR-AML 
patients, because of its association with lower CIR, as well 
as with improved OS and DFS. If NEDD9 overexpression 
is validated in future studies as an independent marker for 
a favorable outcome, it could be used for the development 
of risk-adapted post-remission chemotherapy protocols, to 
treat candidates with high probability of response among 
patients, included within the highly heterogeneous IR-
AML subgroup. Finally, and because of the specificity of 
NEDD9 regulation and function in myeloid cells, it would 
be interesting to determine if the prognostic capacity we 
observed in AML patients for NEDD9 overexpression 
could be extended to other myeloid lineage malignancies. 
MATERIALS AND METHODS
Patients
Patients included in this study were adults up to 
the age of 65 years with de novo IR-AML, according 
Figure 2: Cumulative incidence of relapse according to NEDD9 expression in cohorts. Kaplan–Meier curves represent 
CIR of cohort 1 (A) and cohort 2 (B) depending on the NEDD9 expression. Black line and gray line indicate NEDD9 overexpressed 
and underexpressed, respectively. Gray test for CIR was used to analyze the statistical significance. P < 0.05 was considered statistically 
significant (Bold values). CIR; Cumulative incidence of relapse.
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to the Medical Research Council (MRC) classification 
[34, 35]. All the samples were collected at diagnosis after 
obtaining written informed consent in accordance with 
the Declaration of Helsinki and the Ethics Committee 
approval of each participating institution. A cohort of 
73 patients (Cohort 1) from Hospital de la Santa Creu 
i Sant Pau (Barcelona, Spain) was our initial group, 
whereas another cohort of 206 patients from two other 
hospitals (Cohort 2), Hospital La Fe (Valencia, Spain) 
and Hospital Universitario de Salamanca (Salamanca, 
Spain), was included as a validation group in this study. 
All the patients were selected based on availability of 
bone marrow specimens, between the start and the end 
periods for each hospital trial. Clinical outcomes between 
the selected and non-selected patients of each cohort 
were similar and did not present significant differences 
(Data not shown). Patients older than 65 years or with an 
acute promyelocytic leukemia at diagnosis (M3 in FAB 
Table 4: Association between NEDD9 expression and clinical data in the cohorts of our study
Parameter













Age, 73 55 18 0.726† 204 153 51 0.405†
 < 50 years (%) 34 (47) 27 7 0.588 87 (43) 63 24 0.514
 > 50 years (%) 39 (53) 28 11 117 (57) 90 27
Sex,    
 Male (%) 39 (53) 29 10 1.000 108 (53) 87 21 0.074
 Female (%) 34 (47) 26 8 96 (47) 66 30
WBC, 73 55 18 0.774‡ 202 151 51 0.818‡
 <20 × 109/L (%) 25 (34) 18 7 0.776 107 (53) 82 25 0.521
 >20 × 109/L (%) 48 (66) 37 11 95 (47) 69 26
FAB Classification, (%)   0.026*  0.029*
 M0 8 (11) 7 1 16 (8) 14 2
 M1 23 (32) 21 2 46 (22) 39 7
 M2 6 (8) 6 0 41 (20) 33 8
 M4 12 (16) 8 4 36 (18) 28 8
 M4E 1 (1) 1 0 1 (1) 1 0
 M5 21 (29) 10 11 46 (22) 27 19
 M6 1 (1) 1 0 6 (3) 5 1
 M7 1 (1) 1 0 0 (0) 0 0
Protein mutations, (%)    
 FLT3/ITD− 39 (53) 30 9 1.000 149 (73) 116 33 0.198
 FLT3/ITD+ 29 (40) 22 7 54 (27) 37 17
 NPM1− 31 (43) 22 9 0.779 108 (53) 85 23 0.257
 NPM1+ 33 (45) 25 8 95 (47) 68 27
 FLT3− + NPM1+ (Fav.) 16 (22) 12 4 1.000 60 (30) 43 17 0.476
 Others (Unfav.) 47 (64) 35 12 143 (70) 110 33
Alive (%) 35 (48) 22 13 0.028 105 (51) 72 33 0.035
Death (%) 38 (52) 33 5 99 (49) 81 18
No relapse (%) 42 (71) 31 11 0.737 129 (67) 93 36 0.152
Relapse (%) 17 (29) 14 3 63 (33) 52 11
Results are presented as the number of patients for each characteristic. The percentage of the patients is indicated in brackets 
for each condition. For categorical variables, the Fischer exact test or χ2 test (*) were used to analyze the statistical significance; 
while for continuous variables showing normal or abnormal distribution, the Student’s t-test (†) or the Mann-Whitney U (‡) 
test were used, respectively. P < 0.05 indicates statistical significance (Bold values). WBC; White blood cells. FAB; French-
American-British.
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classification) were excluded from the study. The main 
characteristics of the groups are shown in Table 1.
Cohort 1 and Cohort 2 patients were treated 
according the CETLAM-03 (Grupo Cooperativo para 
el Estudio y Tratamiento de las Leucemias agudas y 
Mielodisplasias) and the PETHEMA trials LMA99, 
LMA2007 and LMA2010 (Programa de Estudio y 
Tratamiento de las Hemopatías Malignas, www.pethema.
org) protocols, respectively.
Concerning the CETLAM-03 protocol, treatment was 
administered between 2003 and 2012 at 21 collaborating 
institutions. In brief, induction chemotherapy included 
one or two courses of idarubicin 12 mg/m2 intravenously 
(IV) days 1, 3, 5, cytarabine 500 mg/m2/12 h over 2 h IV 
infusion days 1, 3, 5, and etoposide 100 mg/m2 IV days 
1, 2, 3. In addition, patients also received G-CSF priming 
150 mg/m2 subcutaneously (SC) from day 0 to the last 
day of induction and consolidation chemotherapy. This 
was followed by one consolidation with mitoxantrone 
12 mg/m2 IV from day 4 to 6, and cytarabine 
500 mg/m2/12 h IV from day 1 to 6. Subsequently, the 
patients went on chemotherapy courses with high-dose 
cytarabine as in the Cancer and Leukemia Group B 
trial [36]. Particularly, patients in intermediate risk group, 
with normal karyotype, a single course of induction 
chemotherapy to achieve the complete remission (CR), 
the absence of adverse molecular features (FLT3-ITD or 
MLL-PTD) and low minimal residual disease (MRD) levels 
after consolidation (MRD < 0,1%) receive an autologous 
peripheral blood stem cells (PBSC) transplant, regardless of 
having an HLA-identical sibling. The PETHEMA protocols 
are detailed in http://www.fundacionpethema.es/. Eligible 
patients were treated with intensive chemotherapy in which 
induction consisted of a combination of anthracycline plus 
cytarabine with or without etoposide. On achievement 
of complete remission (CR) patients proceeded to 
consolidation therapy and eligible cases were selected for 
autologous or allogeneic stem cell transplantation.
Time-dependent clinical outcome endpoints
Overall survival (OS), disease-free survival (DFS) 
and cumulative incidence of relapse (CIR) were assessed 
in the statistical analysis. OS was calculated from the time 
of patient diagnosis to death or last date of follow-up (dead 
vs alive patients) and DFS from the complete remission 
date to relapse/death or last date of follow-up (dead or 
relapsed vs alive patients). Finally, CIR was calculated 
from the complete remission date to relapse or last date of 
follow-up or death (competing risk analysis: relapsed vs 
alive non-relapsed vs dead non-relapsed patients).
RNA extraction and gene expression analyses
Samples were obtained from bone marrow aspirates 
of IR-AML patients at diagnosis. Mononuclear cells were 
isolated by Ficoll-Hypaque gradient and total RNA was 
extracted using TRIzol reagent (Thermo Fisher Scientific, 
Waltham, MA, USA) following the manufacturer’s 
protocol. cDNA was generated after reverse transcription 
of 1.5 µg total RNA using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems (AB), 
Foster City, CA, USA). NEDD9 and BCAR1 expression 
(Hs00610590_m1 and Hs00183953_m1, resp. AB) 
was determined by real-time PCR using the platform 
ABI 7900HT Fast Real-Time PCR System (AB). Each 
sample was assessed by triplicate using the TaqMan 
Gene Expression Assay (AB). The comparative cycle 
threshold (DCt) method was used to determine relative 
expression levels [37], expressed as a ratio between target 
gene and control gene. ABL was used as the endogenous 
control gene (probe: ENP1043, primers: P3035: 
TGGAGATAACACTCTAAGCATAACTAAAGGT, 
P3036: GATGTAGTTGCTTGGGACCCA; AB) using VIC 
fluorophore. Quantitative methods analyses were detailed 
in previous reports also using ABL as control gene [38].
Statistical analysis
Statistical analyses were performed in the IBM 
SPSS Statistics (Release 22.0.0.0, New York, NY, USA). 
The differences between clinical data of the two cohorts 
and the association between the NEDD9 expression and 
clinical data were analyzed using the Fischer exact test 
or χ2 test. Differences between continuous variables were 
analyzed with the Student’s t-test or the Mann-Whitney 
U test in those showing normal or abnormal distribution, 
respectively. Exploratory univariate analyses were 
performed to choose the threshold value to dichotomize 
the NEDD9 and BCAR1 mRNA levels in over and 
underexpression. After analyzing the mean, the median and 
different percentiles the best results were obtained with the 
third quartile (75th percentile) that is the cutoff selected 
to perform this study. Independent variables analyzed 
included age, gender, white blood cell count (WBC) 
at diagnosis, FAB category, and molecular alterations 
(FLT3/ITD, NPM1, and CEBPA). Time-dependent 
endpoints such as OS, DFS and CIR were assessed, and 
the endpoint for the threshold was death and relapse. Time-
dependent outcomes were calculated using Kaplan–Meier 
curves (OS or DFS), and the log-rank test was used for 
comparisons [39]. The regression model used in univariate 
and multivariate analyses was COX test (OS and DFS). 
The free statistical package R Studio (Version 0.98-1102, 
2009–2014, RStudio Inc., Boston, MA, USA) through 
the R version 3.1.2 (2014-10-31, The R Foundation for 
Statistical Computing) [40] was used for the competing 
risk analysis. CIR was analyzed by Gray [41] and Fine 
and Gray’s tests [42], using R Studio and the cuminc 
and crr functions through the cmprsk package. After 
exploratory univariate comparisons, multivariate analyses 
were performed including variables with a p-value below 
Oncotarget76012www.impactjournals.com/oncotarget
0.25 and the INTRO method was used in SPSS to analyze 
Cox regression. Hazard ratios (HR) with relative 95% 
confidence interval (CI) are shown in both univariate and 
multivariate analyses. Any differences were considered to 
be statistically significant when the p-value was < 0.05.
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